GlassScriptPhysician profile
Jeffrey Gould
NPI 1124021399
$26,693.97
in general payments reported to CMS, 2019-2025
72 companies · $3,203 in 2025
The $3,203 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,651 · 2020: $1,611 · 2021: $3,384 · 2022: $3,331 · 2023: $3,504 · 2024: $3,009 · 2025: $3,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,576 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,576.25 |
| Education | $140.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $7,841.29 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $3,138.32 | 2019-2022 | |
| Emd Serono, INC. | $1,498.42 | 2019-2025 | Mavenclad |
| Ucb, INC. | $1,374.38 | 2019-2025 | Zilbrysq, Rystiggo, Briviact |
| Abbvie INC. | $1,111.70 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $1,022.58 | 2019-2025 | Ultomiris, Soliris |
| Csl Behring | $808.26 | 2019-2025 | Hizentra |
| Biogen, INC. | $634.18 | 2019-2025 | Tysabri, Vumerity, Plegridy |
| Novartis Pharmaceuticals Corporation | $632.55 | 2019-2025 | |
| Genentech USA, INC. | $630.90 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $571.70 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Argenx US, INC. | $544.13 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $446.79 | 2020-2025 | Xcopri |
| Lilly USA, LLC | $407.72 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Acadia Pharmaceuticals INC | $390.50 | 2019-2025 | Nuplazid |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Gould listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.